Indeed, it has been shown that in prostate cancer, breast cancer and in leukemia, EZH2 is also recruited to oncogenes to promote gene activation independently of its enzymatic activity (Lee et al., 2011; Xu et al., 2012; Chan and Morey, 2019; Wang et al., 2022). This evidence concerns the gene EZH2 and breast carcinoma.